A detailed history of Macquarie Group LTD transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 500,000 shares of KPTI stock, worth $405,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500,000
Previous 505,684 1.12%
Holding current value
$405,000
Previous $439,000 5.47%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.7 - $1.06 $3,978 - $6,025
-5,684 Reduced 1.12%
500,000 $415,000
Q2 2024

Aug 09, 2024

BUY
$0.87 - $1.58 $4,945 - $8,980
5,684 Added 1.14%
505,684 $439,000
Q1 2024

May 14, 2024

BUY
$0.72 - $1.66 $86,400 - $199,200
120,000 Added 31.58%
500,000 $755,000
Q4 2022

Feb 21, 2023

SELL
$2.48 - $5.93 $3,633 - $8,687
-1,465 Reduced 0.38%
380,000 $1.29 Million
Q3 2022

Nov 14, 2022

SELL
$4.08 - $5.82 $2,350 - $3,352
-576 Reduced 0.15%
381,465 $2.09 Million
Q2 2021

Aug 13, 2021

BUY
$8.11 - $11.11 $7,964 - $10,910
982 Added 0.26%
382,041 $3.94 Million
Q1 2021

May 14, 2021

SELL
$9.85 - $17.69 $2,689 - $4,829
-273 Reduced 0.07%
381,059 $4.01 Million
Q2 2020

Aug 11, 2020

BUY
$16.6 - $25.25 $22,111 - $33,633
1,332 Added 0.35%
381,332 $7.22 Million
Q1 2019

May 15, 2019

SELL
$4.12 - $10.25 $1,236 - $3,075
-300 Reduced 0.08%
380,000 $2.22 Million
Q4 2018

Feb 15, 2019

BUY
$8.2 - $16.95 $345,219 - $713,595
42,100 Added 12.45%
380,300 $3.56 Million
Q3 2018

Nov 15, 2018

SELL
$17.03 - $21.18 $40,872 - $50,832
-2,400 Reduced 0.7%
338,200 $5.76 Million
Q2 2018

Aug 14, 2018

BUY
$12.0 - $19.88 $4.09 Million - $6.77 Million
340,600 New
340,600 $5.79 Million
Q1 2018

May 11, 2018

SELL
$9.92 - $17.25 $8,928 - $15,525
-900 Closed
0 $0
Q4 2017

Feb 15, 2018

BUY
$9.15 - $11.99 $8,235 - $10,791
900
900 $9,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $64.6M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.